Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated
